- Home
- ATRA vs ARMP Comparison
ATRA vs ARMP Comparison
Compare ATRA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | ARMP |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 125.7M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATRA | ARMP |
|---|---|---|
| Price | $16.92 | $6.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $25.00 | $9.00 |
| AVG Volume (30 Days) | ★ 74.4K | 45.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $151,930,000.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.79 | ★ N/A |
| Revenue Growth | ★ 51.27 | N/A |
| 52 Week Low | $5.01 | $0.90 |
| 52 Week High | $18.95 | $16.34 |
Technical Indicators
Market Signals| Indicator | ATRA | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 56.96 |
| Support Level | $16.51 | $6.09 |
| Resistance Level | $18.95 | $6.54 |
| Average True Range (ATR) | 1.37 | 0.53 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 59.80 | 100.00 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.